MKI67 and breast cancer: The trial’s findings showed that the ribociclib+ alpelisib+ letrozole combination caused a more consistent reduction of Ki-67, suggesting that targeting both CDK4/6 and PI3K may lead to better health outcomes for BC patients [97].